Afinitor licensed in advanced breast cancer

Afinitor (everolimus) is now licensed for the treatment of advanced breast cancer.

by
Everolimus targets mTOR, an important regulator of tumour cell division, blood vessel growth and cell metabolism. | SCIENCE PHOTO LIBRARY
Everolimus targets mTOR, an important regulator of tumour cell division, blood vessel growth and cell metabolism. | SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package